Evidence map›Paper›PMID 24117863›Full record

ArticleJournal of neurochemistry2014

Molecular mechanism of ERK dephosphorylation by striatal-enriched protein tyrosine phosphatase.

Rong Li, Di-Dong Xie, Jun-Hong Dong, Hui Li, Kang-Shuai Li, Jing Su, Lai-Zhong Chen, Yun-Fei Xu, Hong-Mei Wang, Zheng Gong and 12 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Journal of neurochemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Regulation of Phosphorylated State of NMDA Receptor by STEPAntioxidants (Basel, Switzerland) · 2021
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Regulation of ERK Kinase by MEK1 Kinase Inhibition in the Brain.The Journal of biological chemistry · 2015
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 2 countries.

Rong Li *Key Laboratory Experimental Teratology of the Ministry of Education and Department of Biochemistry and Molecular Biology, Shandong University, School of Medicine, Jinan, Shandong, 250012, China.
Di-Dong Xie *Key Laboratory Experimental Teratology of the Ministry of Education and Department of Biochemistry and Molecular Biology, Shandong University, School of Medicine, Jinan, Shandong, 250012, China.
Jun-Hong Dong *Key Laboratory Experimental Teratology of the Ministry of Education and Department of Biochemistry and Molecular Biology, Shandong University, School of Medicine, Jinan, Shandong, 250012, China.
Hui LiKey Laboratory Experimental Teratology of the Ministry of Education and Department of Biochemistry and Molecular Biology, Shandong University, School of Medicine, Jinan, Shandong, 250012, China.
Kang-Shuai LiKey Laboratory Experimental Teratology of the Ministry of Education and Department of Biochemistry and Molecular Biology, Shandong University, School of Medicine, Jinan, Shandong, 250012, China.
Jing SuKey Laboratory Experimental Teratology of the Ministry of Education and Department of Biochemistry and Molecular Biology, Shandong University, School of Medicine, Jinan, Shandong, 250012, China.
Lai-Zhong ChenSchool of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, 250012, China.
Yun-Fei XuKey Laboratory Experimental Teratology of the Ministry of Education and Department of Biochemistry and Molecular Biology, Shandong University, School of Medicine, Jinan, Shandong, 250012, China.
Hong-Mei WangKey Laboratory Experimental Teratology of the Ministry of Education and Department of Biochemistry and Molecular Biology, Shandong University, School of Medicine, Jinan, Shandong, 250012, China.
Zheng GongKey Laboratory Experimental Teratology of the Ministry of Education and Department of Biochemistry and Molecular Biology, Shandong University, School of Medicine, Jinan, Shandong, 250012, China.
Guo-Ying CuiKey Laboratory Experimental Teratology of the Ministry of Education and Department of Biochemistry and Molecular Biology, Shandong University, School of Medicine, Jinan, Shandong, 250012, China.
Xiao YuKey Laboratory Experimental Teratology of the Ministry of Education and Department of Biochemistry and Molecular Biology, Shandong University, School of Medicine, Jinan, Shandong, 250012, China.
Kai WangDepartment of Physiology, Shandong University, School of Medicine, Jinan, Shandong, 250012, China.
Wei YaoDepartment of Physiology, Shandong University, School of Medicine, Jinan, Shandong, 250012, China.
Tao XinProvincial Hospital affiliated to Shandong University, Jinan, Shandong, 250012, China.
Min-Yong LiSchool of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, 250012, China.
Kun-Hong XiaoDepartment of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Xiao-Fei AnDrug Discovery Center, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China, 518055.
Yuqing HuoVascular Biology Center, Department of Cellular Biology and Anatomy, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912.
Zhi-Gang XuShandong Provincial School Key laboratory for Protein Science of Chronic Degenerative Diseases, Jinan, Shandong, 250012, China.
Jin-Peng SunKey Laboratory Experimental Teratology of the Ministry of Education and Department of Biochemistry and Molecular Biology, Shandong University, School of Medicine, Jinan, Shandong, 250012, China.
Qi PangProvincial Hospital affiliated to Shandong University, Jinan, Shandong, 250012, China.
Shandong University · CNQilu Hospital of Shandong University · CNShandong Provincial Hospital · CNAugusta University · USDuke Medical Center · USPeking University · CNShandong Academy of Pharmaceutical Sciences · CNWeihai Science and Technology Bureau · CN

Funding

The role of adenosine kinase in atherosclerosisR01HL095556 · NHLBI · UNIVERSITY OF MINNESOTA · PI HUO, YUQING · 2011 to 2015
$1.5M
The role of neutrophil recruitment in arterial diseasesR21HL108922 · NHLBI · UNIVERSITY OF MINNESOTA · PI HUO, YUQING · 2011 to 2013
$405k
NHLBI NIH HHS HL095556NHLBI NIH HHS HL108922NHLBI NIH HHS R01 HL095556NHLBI NIH HHS R21 HL108922
6 · The paper itself

Abstract

Striatal-enriched tyrosine phosphatase (STEP) is an important regulator of neuronal synaptic plasticity, and its abnormal level or activity contributes to cognitive disorders. One crucial downstream effector and direct substrate of STEP is extracellular signal-regulated protein kinase (ERK), which has important functions in spine stabilisation and action potential transmission. The inhibition of STEP activity toward phospho-ERK has the potential to treat neuronal diseases, but the detailed mechanism underlying the dephosphorylation of phospho-ERK by STEP is not known. Therefore, we examined STEP activity toward para-nitrophenyl phosphate, phospho-tyrosine-containing peptides, and the full-length phospho-ERK protein using STEP mutants with different structural features. STEP was found to be a highly efficient ERK tyrosine phosphatase that required both its N-terminal regulatory region and key residues in its active site. Specifically, both kinase interaction motif (KIM) and kinase-specific sequence of STEP were required for ERK interaction. In addition to the N-terminal kinase-specific sequence region, S245, hydrophobic residues L249/L251, and basic residues R242/R243 located in the KIM region were important in controlling STEP activity toward phospho-ERK. Further kinetic experiments revealed subtle structural differences between STEP and HePTP that affected the interactions of their KIMs with ERK. Moreover, STEP recognised specific positions of a phospho-ERK peptide sequence through its active site, and the contact of STEP F311 with phospho-ERK V205 and T207 were crucial interactions. Taken together, our results not only provide the information for interactions between ERK and STEP, but will also help in the development of specific strategies to target STEP-ERK recognition, which could serve as a potential therapy for neurological disorders. Regulation of phospho-ERK by STEP underlies important neuronal activities. A detailed enzymologic characterisation and cellular studies of STEP revealed that specific residues in KIM and active site mediated ERK recognition. Structural differences between the KIM-ERK interfaces and the active site among different ERK phosphatases could be targeted to develop specific STEP inhibitor, which has therapeutic potential for neurological disorders. PKA, protein kinase A & NGF, nerve growth factor.

Indexed as

Amino Acid SequenceAnimalsCatalytic DomainMitogen-Activated Protein Kinase 1Models, MolecularMolecular Sequence DataMutationPC12 CellsPhosphorylationProtein Tyrosine Phosphatases, Non-ReceptorRatsMitogen-Activated Protein Kinase 1Protein Tyrosine Phosphatases, Non-ReceptorPtpn5 protein, ratERKneurological disordersphosphatasephosphorylationstriatal enriched tyrosine phosphatasessynaptic plasticity

Identifiers

PMID24117863
PMCPMC3947313
OpenAlexW2007209499

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.